Arcturus Therapeutics Holdings Inc. (ARCT) News
Track canonical SquawkNews coverage tagged to ARCT, Arcturus Therapeutics Holdings Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Arcturus Therapeutics shares are trading higher after the company announced a strategic collaboration with Thermo Fisher Scientific to help
Arcturus Therapeutics shares are trading higher after the company announced a strategic collaboration with Thermo Fisher Scientific to help support the Phase 3 development and potential commercialization of ARCT-032. Als
EQUITY | Jul 02, 2026, 03:39 PM UTC
H
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) is collaborating with Thermo Fisher Scientific Inc. (NYSE: TMO ) to support the Phase 3 development and potential commercialization of ARCT-032, the company’s investiga
MACRO | Jul 02, 2026, 03:32 PM UTC
L
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Jef
EQUITY | Jul 02, 2026, 11:21 AM UTC
L
Arcturus Therapeutics Collaborates With Thermo Fisher Scientific To Help Support Phase 3 Development And Potential Commercialization Of ARCT
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights Arcturus Therapeutics Holdings Inc. (("Arcturus", NASDAQ: ARCT ), a messenger RNA medicines company focused on the de
EQUITY | Jul 02, 2026, 11:02 AM UTC
L
Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27
Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ: ARCT ) with a Buy rating and announces Price Target of $27.
EQUITY | Jul 02, 2026, 09:47 AM UTC